| PBM licensure required | Required by statute |
| Spread pricing banned (Medicaid) | Banned in Medicaid |
| Pharmacist gag clauses prohibited | Prohibited by statute |
| Copay accumulator banned | Banned by statute |
Washington requires PBM licensure or registration before operating in the state, with renewal cycles, fee schedules, and disclosure requirements set by statute or rule. State licensure authority typically vests in the Washington Board of Pharmacy or the Department of Insurance, depending on whether the PBM regulation is framed as pharmacy practice or insurance regulation. Following Rutledge v PCMA (2020), state PBM regulation that does not directly conflict with ERISA preemption is permissible, and most states have enacted or strengthened PBM oversight statutes in the post-Rutledge period.
Washington Medicaid program has adopted a spread-pricing transparency or pass-through model for pharmacy claims processed through Medicaid Managed Care PBMs. Pass-through pricing requires PBMs to charge the Medicaid plan exactly what they reimburse to dispensing pharmacies (typically benchmarked to NADAC plus a dispensing fee), eliminating the historic "spread" margin where PBMs charged plans more than they paid pharmacies. Commercial market spread-pricing rules are typically narrower and require disclosure rather than outright prohibition. Verify the current Washington Medicaid pharmacy benefit contract structure and any updated commercial-market rules with the Washington Department of Insurance.
Washington has enacted a Maximum Allowable Cost (MAC) appeal statute giving pharmacies a defined process to challenge PBM reimbursement at or below acquisition cost. Standard elements include: a defined appeal window (typically 7-30 days from claim adjudication), PBM duty to respond within a statutory timeframe, disclosure of MAC pricing source, and a process for retroactive correction when the appeal succeeds. The statute typically applies to generic drugs reimbursed at MAC and is enforced by the Washington Board of Pharmacy or Department of Insurance, with civil penalties for non-compliance. Independent pharmacies are the primary beneficiaries of MAC appeal protections.
Pharmacist gag clauses (PBM contract provisions prohibiting pharmacists from informing patients of lower cash-pay or competitor prices) are prohibited under both federal law (Patient Right to Know Drug Prices Act, 2018, for Medicare; Know the Lowest Price Act, 2018, for commercial coverage) and parallel Washington statutes that often extend additional protections. Pharmacists may disclose cash-pay or competitor pricing to patients without violating PBM network contracts. Verify any Washington-specific additional protections (such as duty-to-disclose lower prices) with the Washington Board of Pharmacy.
Washington has enacted a copay accumulator prohibition requiring health plans and PBMs to count manufacturer copay assistance toward the patient's out-of-pocket maximum and deductible. Without this prohibition, plans using "copay accumulator" or "copay maximizer" programs do not apply manufacturer assistance to the patient's deductible, exposing the patient to full deductible exposure once the manufacturer card is exhausted. The Washington statute applies to fully-insured plans regulated by state Department of Insurance; self-insured ERISA plans remain governed by federal law and are not bound by the state statute.
Washington does not currently have a broad statutory any willing pharmacy (AWP) requirement. PBMs operating in Washington commercial markets may exclude pharmacies from preferred-pharmacy networks subject to general antitrust and contract-formation rules. Patients in plans with narrow preferred-pharmacy networks face higher cost-sharing if filling at out-of-network pharmacies. Verify current Washington statutory status with the Washington Department of Insurance; AWP legislation has been periodically debated in many state legislatures.
PBM regulation sets the rules; pharmacy-level discount strategy decides the actual price you pay. See our sister site RxGrab's Washington generic substitution + Medicaid + SPAP reference for the consumer-side of the question.
Find patient assistance options for your medication with our Assistance Finder, check for drug interactions with the Interaction Checker, or look up your plan's formulary with the Formulary Checker. All tools work nationwide.
Yes. Washington requires PBMs to obtain state licensure or registration before operating in the state. Following Rutledge v PCMA (2020), state PBM regulation that does not directly conflict with ERISA preemption is permissible, and Washington is among the majority of states that have enacted formal licensure requirements. See the PBM licensure section above for specific authority and statutory framework.
Yes. Pharmacist gag clauses are prohibited under both federal law (Patient Right to Know Drug Prices Act, 2018) and Washington's parallel statute, so pharmacists may disclose cash-pay or competitor pricing without violating their PBM contract. Always ask: "What's the cash price?" before running a prescription through insurance, it's sometimes lower than the insurance copay, especially for cheap generics.
Yes. Washington has enacted a copay accumulator prohibition requiring fully-insured health plans to count manufacturer copay assistance toward your deductible and out-of-pocket maximum. Note: this protection applies to state-regulated fully-insured plans. Self-insured ERISA plans (which cover roughly 60% of US workers) remain governed by federal law and may still use accumulators.
Subject to your specific health plan's pharmacy network. If your plan uses a "preferred pharmacy network," you generally pay less at preferred pharmacies and more (or sometimes nothing covered) at non-preferred ones. Washington does not have a broad any-willing-pharmacy statute, so PBMs may exclude pharmacies from preferred networks subject to general antitrust rules. Always confirm your specific medication's network status before filling.